We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Method Extends Range of Bacteriophage-based Applications

By LabMedica International staff writers
Posted on 04 Jul 2017
A team of Israeli molecular microbiologists developed a method for extending the host specificity of bacteriophage particles to enable them to transfer DNA into a wide range of pathogenic bacteria.

A major limitation in using bacteriophage-based applications is their narrow host range. More...
Approaches for extending the host range have focused primarily on lytic phages in hosts supporting their propagation rather than approaches for extending the ability of DNA transduction into phage-restrictive hosts.

To extend the host range of T7 phage for DNA transduction, investigators at Tel Aviv University (Israel) designed a novel class of hybrid particles that displayed various bacteriophage tail/tail fiber protein combinations. The investigators programmed these modular particles to package and transduce DNA into hosts that normally restricted T7 phage propagation.

The investigators also developed an innovative generalizable platform that considerably enhanced DNA transfer into new hosts by artificially selecting tails that efficiently transduced DNA. In addition, they demonstrated that the hybrid particles were able to transduce desired DNA into desired hosts.

"DNA manipulation of pathogens includes sensitization to antibiotics, killing of pathogens, disabling pathogens' virulence factors, and more," said senior author Dr. Udi Qimron, professor of clinical microbiology and immunology at Tel Aviv University. "We have developed a technology that significantly expands DNA delivery into bacterial pathogens. This may indeed be a milestone, because it opens up many opportunities for DNA manipulations of bacteria that were impossible to accomplish before. This could pave the way to changing the human microbiome - the combined genetic material of the microorganisms in humans - by replacing virulent bacteria with a-virulent bacteria and replacing antibiotic-resistant bacteria with antibiotic-sensitive bacteria, as well as changing environmental pathogens. We have applied for a patent on this technology and are developing products that would use this technology to deliver DNA into bacterial pathogens, rendering them a-virulent and sensitive to antibiotics."

The bacteriophage study was published in the June 1, 2017, issue of the journal Molecular Cell.

Related Links:
Tel Aviv University


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.